Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China

BACKGROUND: Serum phosphorus control is critical for chronic kidney disease (CKD) 5D patients. Currently, clinical profile for an oral phosphorus binder in the mainland Chinese population is not available. OBJECTIVE: To establish the efficacy, safety, and tolerability of lanthanum carbonate in CKD 5...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Xu, Jing, Zhang, Yi-Xiang, Yu, Xue-Qing, Liu, Zhi-Hong, Wang, Li-Ning, Chen, Jiang-Hua, Fan, Ya-Ping, Ni, Zhao-Hui, Wang, Mei, Yuan, Fa-Huan, Ding, Guo-Hua, Chen, Xiang-Mei, Zhang, Ai-Ping, Mei, Chang-Lin
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3570485/
https://ncbi.nlm.nih.gov/pubmed/23379590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2369-14-29
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items